AIM Biotech
AIM Biotech is a leading bioengineering company, offering scalable, cost-effective 3D cell culture platforms, drug screening services, and customized assay development. By combining model realism and platform simplicity, AIM’s plug-and-play technologies empower drug developers to mimic human biology with precision, delivering clinically-relevant data.
Nilogen Oncosystems
Provision of untouched intact tumor tissue platform to allow for the investigation of clinical relevant biomarkers, mechanism of action, safety and efficacy of therapeutics.
Dynamic42 GmbH
Dynamic42 has developed a PDMS-free, easy-to-handle, affordable OoC platform. We specialize in vascular, liver, lung and intestinal biology and infection models. We further enable scientists with training courses to establish their own OoC models.
Axol BioScience
Axol Bioscience are leaders in human iPSC products and services for CNS, PNS and cardiac research. Under ISO9001, we manufacture functional hiPSC-derived cells with multi-platform utility for MPS technology, alongside a “one-stop shop” of iPSC lines, services and custom assays.
Neurosetta, LLC
Providing next-generation HUMAN developmental neurotoxicity risk assessment to accelerate and reduce the cost of your chemical or drug discovery and development pipeline
PredictCan Biotechnologies
“PredictCan Biotechnologies has patented cell education technology that exploits the intrinsic plasticity of cell lines by inducing subject-dependent phenotypic changes to better model cohorts of healthy or pathological individuals with tailored characteristics. The company generates state-of-the-art 3D individual-centric models for early detection of cancers, drug discovery, drug safety, and drug efficacy. Among our models, GenuineSelect-TOX is a platform that accurately detects intrinsic DILI and immune-mediated idiosyncratic DILI (iDILI) during the early and late stages of drug development.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
AnaBios
AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies, including superior quality human tissue samples and functional assays focused, as well as human primary cells through its subsidiary Cell Systems.